or Try an Advanced Search...

    Technical Analysis for NAUT - Nautilus Biotechnology, Inc.

    Grade Last Price % Change Price Change
    D 2.51 -5.64% -0.15
    NAUT closed down 7.96 percent on Thursday, November 7, 2024, on 1.9 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NAUT trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish -5.64%
    Fell Below 50 DMA Bearish -5.64%
    180 Bearish Setup Bearish Swing Setup -5.64%
    Cup with Handle Other -5.64%
    Outside Day Range Expansion -5.64%
    Gapped Down Weakness -5.64%
    Crossed Above 20 DMA Bullish -13.15%
    Crossed Above 200 DMA Bullish -13.15%
    Crossed Above 50 DMA Bullish -13.15%
    Pocket Pivot Bullish Swing Setup -13.15%
    Older End-of-Day Signals for NAUT ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 3 hours ago
    Down 5% about 3 hours ago
    Fell Below Lower Bollinger Band about 3 hours ago
    Down 1 ATR about 3 hours ago
    60 Minute Opening Range Breakdown about 5 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NAUT Chart by TradingView
    Basic chart:

    Profile

    Nautilus Biotechnology, Inc. operates as biotech company that develops a platform using computational techniques, cloud computing, AI technologies, and blood tests to detect cancer and potentially other health issues at an early stage. Nautilus Biotechnology, Inc. was formerly known as Ignite Biosciences, Inc. The company was incorporated in 2016 and is based in San Carlos, California.
    Classification
    Sector: Industrials
    Industry: Conglomerates
    Keywords: Biotechnology Cancer Cloud Computing Software Ai Technologies

    Is NAUT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
    Oct 30 Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
    Aug 14 Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    Jul 30 Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript
    Jul 30 Nautilus Biotechnology GAAP EPS of -$0.14 beats by $0.02
    Jul 30 Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
    Jul 2 With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future
    May 23 Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    See more NAUT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.4547
    52 Week Low 2.19
    Average Volume 76,648
    200-Day Moving Average 2.66
    50-Day Moving Average 2.76
    20-Day Moving Average 2.76
    10-Day Moving Average 2.69
    Average True Range 0.16
    RSI (14) 47.09
    ADX 13.54
    +DI 20.29
    -DI 17.23
    Chandelier Exit (Long, 3 ATRs) 2.55
    Chandelier Exit (Short, 3 ATRs) 2.94
    Upper Bollinger Bands 2.99
    Lower Bollinger Band 2.53
    Percent B (%b) 0.28
    BandWidth 16.38
    MACD Line -0.02
    MACD Signal Line -0.02
    MACD Histogram -0.0059
    Fundamentals Value
    Market Cap 332.42 Million
    Num Shares 125 Million
    EPS -0.47
    Price-to-Earnings (P/E) Ratio -5.66
    Price-to-Sales 0.00
    Price-to-Book 1.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.05
    Resistance 3 (R3) 3.09 3.00 2.98
    Resistance 2 (R2) 3.00 2.91 2.98 2.96
    Resistance 1 (R1) 2.83 2.84 2.79 2.79 2.94
    Pivot Point 2.75 2.75 2.72 2.72 2.75
    Support 1 (S1) 2.57 2.65 2.53 2.53 2.38
    Support 2 (S2) 2.49 2.59 2.47 2.36
    Support 3 (S3) 2.32 2.49 2.34
    Support 4 (S4) 2.27